Search the Newsreel

Knowledge graphs: Turning fragmented biomedical data into connected, actionable insight

This article discusses how knowledge graphs address the challenge of fragmented biomedical data, transforming it into actionable insights. It highlights that the problem is not data abundance but usability, with knowledge graphs connecting disparate data points into a unified framework. The piece also explains …

Owens Corning (OC) Is Up 8.5% After Q2 Earnings Beat, Buybacks And CFO Transition – What's Changed

In early August 2026, Owens Corning reported second-quarter 2026 results showing broadly flat sales at US$2,756 million year on year, but a decline in net income to US$226 million and lower earnings per share compared with the prior-year quarter. Alongside these results, the company …

Clarivate Plc (CLVT) Stock Forecasts

Clarivate Plc (CLVT) is a data, information, and software workflow solutions company, primarily serving academia, government, law, life sciences, and healthcare sectors. An analyst report from Morningstar on August 6, 2026, suggests that Clarivate is in the early stages of a multiyear turnaround. The …

Aclaris Therapeutics (NASDAQ:ACRS) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Aclaris Therapeutics Inc earnings beat by $0.01, revenue topped estimates

Aclaris Therapeutics Inc (NASDAQ: ACRS) reported a second-quarter EPS of $-0.150, surpassing analyst estimates by $0.01. The company also exceeded revenue expectations, bringing in $1.6M against a consensus of $1.38M. Aclaris Therapeutics' stock has shown strong performance, increasing by 29.010% in the last three …

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib for Moderate to Severe Lichen Planus

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has been granted Fast Track Designation by the FDA for its investigational drug modzatinib, intended for the treatment of moderate to severe lichen planus. This designation will expedite the development and review process for the therapy, which currently has …

Aclaris Therapeutics (ACRS) Releases Q2 2026 Earnings: Revenue Declines, Losses Narrow

FDA grants fast track status to Aclaris’ lichen planus drug By Investing.com

Aclaris Therapeutics Inc. (NASDAQ:ACRS) has received Fast Track Designation from the FDA for its drug modzatinib (ATI-2138) to treat moderate to severe lichen planus. This designation will accelerate the development and review process for the drug, which addresses an unmet medical need as there …

ASX Penny Stocks Spotlight Clarity Pharmaceuticals And 2 More Compelling Picks

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Press Release: Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

This press release from Aclaris Therapeutics announces its financial results for the second quarter of 2026, alongside corporate and clinical updates. The report will likely detail key financial metrics, provide insights into their ongoing clinical trials, and offer a broader corporate overview for investors …

Aclaris Therapeutics reports Q2 2026 net loss of $21.5M, cash runway through 2028

Aclaris Therapeutics reported a Q2 2026 net loss of $21.5 million, with cash, cash equivalents, and marketable securities totaling $170.6 million as of June 30, 2026. The company expects its cash runway, bolstered by an additional $40.2 million from ATM sales, to fund operations …

Earnings Flash (ACRS) Aclaris Therapeutics, Inc. Reports Q2 Revenue $1.6M, vs. FactSet Est of $1.4M

Aclaris Therapeutics, Inc. (ACRS) announced its Q2 revenue of $1.6 million, surpassing the FactSet estimate of $1.4 million. The biopharmaceutical company also recently received Fast-Track Designation for its inflammation treatment, Modzatinib, and was added to several Russell and S&P indices. The company is engaged …

Earnings Flash (ACRS) Aclaris Therapeutics Posts Q2 Net Loss $0.15 a Share, vs. FactSet Est of $0.16 Loss

Clarivate Insider Sold Shares Worth $4,829,859, According to a Recent SEC Filing

An insider at Clarivate Plc reportedly sold shares valued at $4,829,859, as per a recent SEC filing. The article, published by MT Newswires, provides this financial transaction detail but restricts the full content to members. Clarivate Plc is a provider of transformative intelligence solutions …

Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development

Expanded capabilities across Cortellis portfolio help life sciences organizations turn trusted intelligence into action and accelerate decision making across the research and development lifecycle LONDON, Aug. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the expansion …

Aclaris Therapeutics (ACRS) Earnings Date and Reports 2026 $ACRS

Andrew Miles Snyder Sells 2,489,618 Shares of Clarivate (NYSE:CLVT) Stock

Clarivate director Andrew Miles Snyder sold 2,489,618 shares of CLVT stock at an average price of $1.94, totaling approximately $4.83 million, reducing his direct ownership by 39.23%. This transaction occurred as Clarivate shares traded near their 52-week low and the company reported quarterly EPS …

Aclaris Therapeutics (NASDAQ: ACRS) CSO gets shares, some withheld

Aclaris Therapeutics' Chief Scientific Officer, Roland Kolbeck, had 36,375 restricted stock units vest, converting into common shares on August 1, 2026. Of these, 12,385 shares were withheld for tax obligations at $5.20 per share. Kolbeck still holds 109,125 RSUs that will vest in future …

Arrowstreet Capital Limited Partnership Acquires Shares of 1,320,982 Clarivate PLC $CLVT

Arrowstreet Capital Limited Partnership recently acquired 1,320,982 shares of Clarivate PLC (NYSE:CLVT) worth approximately $3.34 million, marking a new position and a 0.21% stake in the company. Despite Clarivate beating analyst EPS estimates with $0.19, its revenue of $587.3 million fell short of expectations …

Weekly Recap: Clarivate PLC Q2 2026 results and Michael Easton named CFO

Clarivate PLC (NYSE:CLVT) reported Q2 2026 results including $587.3M revenue, a GAAP loss of $268.6M, but adjusted net income of $123.1M and adjusted EBITDA of $247.2M. Michael Easton will become the new CFO on August 8, 2026, replacing Jonathan Collins. Following the results, Stifel …

Form 144 Clarivate Plc For: 3 August By Investing.com

This article from Investing.com reports the filing of Form 144 for Clarivate Plc on August 3rd. It briefly mentions Clarivate's stock symbol CLVT and its stock performance (+1.55%). The article also includes various market data like indices, commodities, and share prices, though these appear …

Could Clarity Pharmaceuticals (ASX:CU6) Be Australia's Next Small-Cap Healthcare Surprise?

Clarivate (CLVT) plans potential NYSE sale of ProQuest merger consideration shares

Clarivate plc has filed a Form 144 notice indicating a potential sale of 2,489,618 ordinary shares on the NYSE through J.P. Morgan Securities LLC. These shares were originally acquired on December 1, 2021, as consideration for the merger of ProQuest LLC into Clarivate. The …

Clarivate PLC $CLVT Shares Sold by Dimensional Fund Advisors LP

Clarivate (NYSE:CLVT) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen has downgraded Clarivate (NYSE:CLVT) from a "Buy" to a "Hold" rating. This move contributes to an overall bearish sentiment among analysts, with the stock currently holding a consensus "Reduce" rating and an average price target of $3.02. Clarivate's shares opened at …

Clarivate (CLVT) Stock Slumps As Impairment Loss Clouds AI Progress

Clariane SE (KRNMF) (H1 2026) Earnings Call Highlights: Strong EBITDA Growth and Refinancing ...

This article first appeared on GuruFocus. Release Date: July 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Clariane SE (KRNMF) delivered a strong 14.9% pro forma increase in pre-IFRS 16 EBITDA, with …

Clarivate (NYSE:CLVT) Price Target Lowered to $5.00 at Stifel Nicolaus

Stifel Nicolaus has lowered its price target for Clarivate (NYSE:CLVT) from $6.00 to $5.00, while maintaining a "buy" rating, indicating a potential 149% upside from its current share price of $2.00. Despite beating EPS estimates, the company's Q2 revenue of $587.3 million missed expectations …

Clarivate PLC (NYSE:CLVT) Given Average Rating of "Reduce" by Brokerages

Clarivate PLC (NYSE:CLVT) has received a consensus "Reduce" rating from seven brokerages, with an average 12-month price target of $2.88. Despite slightly beating adjusted EPS estimates, the company's revenue declined 5.5% year-over-year and fell short of expectations, indicating ongoing profitability challenges. Several institutional investors …

ADAR1 Capital Management LLC Sells 481,560 Shares of Aclaris Therapeutics, Inc. $ACRS

Aclaris Therapeutics (ACRS) Projected to Post Quarterly Earnings on Thursday

Clarivate PLC (CLVT) Q2 2026 Earnings Call Highlights: Strategic Shifts and AI Innovations ...

This article first appeared on GuruFocus. Release Date: July 29, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Clarivate PLC (NYSE:CLVT) reported an improvement in organic Annual Contract Value (ACV) growth to 1.5% …

Clarivate (NYSE: CLVT) promotes Michael Easton to CFO role

Clarivate Plc announced the promotion of Michael Easton to Executive Vice President & Chief Financial Officer, effective August 8, 2026, following Jonathan Collins' resignation. Easton, previously Senior Vice President, Finance & Chief Accounting Officer, will receive a $600,000 base salary, 100% target annual bonus, …

First-half 2026 results

Clariane Half-Year Results: strong improvement in operating performance Successful refinancing transactions Objectives confirmed Strong improvement in operating performance Revenue as at 30 June 2026 stood at €2,699m, up +4.6% on an organic basis supported by volume growth of +1.6% and price gain of +3.0% …

RiskMark wins Best AI Tool For Lawyers at the 2026 CODiE awards

RiskMark, an AI-powered trademark risk assessment solution by Clarivate, has won the Best AI Tool for Lawyers at the 2026 CODiE Awards, following its 2025 LegalTech Breakthrough Award. The platform helps legal professionals assess the likelihood of confusion, identify potential trademark conflicts, and develop …